The Food and Drug Administration yesterday alerted pharmacy and nursing professionals to a voluntary recall of seven lots of an injectable drug used to treat certain serious bacterial infections, which may contain glass particulate matter. The Teva Pharmaceuticals Amikacin Sulfate Injection USP vials were distributed nationwide through wholesalers, retailers and pharmacies. Anyone with an existing inventory of the recalled lots should stop using and quarantine the product immediately, FDA said. Health care professionals and patients are encouraged to report adverse events or side effects related to the use of the product to the FDA's MedWatch program.

Related News Articles

Headline
The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response yesterday released resources focused on…
Headline
The Federal Emergency Management Agency this month issued COVID-19 pandemic operational guidance for the forthcoming hurricane season. Included in the document…
Headline
The Committee on Ways and Means today convened a hearing examining the disproportionate effect COVID-19 is having on minority communities. “Many communities…
Perspective
In Michigan, African Americans make up 14% of the population … but account for 40% of the COVID-19 deaths. In Chicago: 30% of the population … and 46% of the…
Headline
The Department of Health and Human Services’ Office of Minority Health May 1 announced it will provide funding to help deliver important COVID-19-related…
Headline
Hospitals and health systems continue to provide care for our most vulnerable communities by addressing social needs, educating on COVID-19 risks and…